news

31 Maggio 2023

Business Wire – 31/05/2023

IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
Do you like it?
Read more
13 Gennaio 2023

Business Wire – 12/01/2023

IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
Do you like it?
Read more
26 Luglio 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
Do you like it?
Read more
29 Giugno 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
Do you like it?
Read more
24 Maggio 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
Do you like it?
Read more
31 Marzo 2022

Business Wire – 31/03/22

IAMA Therapeutics Announces Formation of Scientific Advisory Board
Do you like it?
Read more
11 Febbraio 2022

Business Wire – 29/03/22

IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
Do you like it?
Read more
iama-3
IAMA Therapeutics S.r.l.
iamatherapeutics@legalmail.it
Vat: 02775040997
Address
Via Filippo Turati, 2
16128 Genoa Italy
Contact
info@iamatherapeutics.com

Cookie Policy - Privacy Policy
Powered by Hetaweb - www.hetaweb.it